| Mo, Xiaodong |
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease |
|
|
| Recruiting | 3 | 182 | RoW | Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Graft-versus-host Disease | 10/29 | 12/30 | | |
ABSK021-201, NCT06186804: A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD) |
|
|
| Enrolling by invitation | 2 | 64 | RoW | ABSK021 | Abbisko Therapeutics Co, Ltd | cGvHD | 10/26 | 12/26 | | |
NCT06149390: ASCT Versus Chemotherapy as First-Line Consolidation Therapy inT-Cell Lymphoma |
|
|
| Completed | N/A | 347 | NA | consolidation with ASCT, consoliation therapy | Huazhong University of Science and Technology, Peking University People's Hospital, Ruijin Hospital, West China Hospital | T-cell Lymphoma Adults | 01/22 | 07/23 | | |
NCT06301425: MRD Response-adapted Allo-HSCT for Adverse-risk AML |
|
|
| Recruiting | N/A | 178 | RoW | Intervention group, Control group | Peking University People's Hospital, Ruijin Hospital, Wuhan TongJi Hospital, Anhui Provincial Hospital | Acute Myeloid Leukemia | 05/27 | 05/28 | | |
NCT06671717: Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma |
|
|
| Not yet recruiting | N/A | 25 | RoW | Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation | Peking University People's Hospital, Ruijin Hospital, Wuhan TongJi Hospital, West China Hospital | Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma | 04/27 | 07/27 | | |
